Tuesday 18 March, 2008

1st para IV filer Sun got final approval on Amifostine injection

Sun Pharma. announced that USFDA has granted final approval to market a generic version of MedImmune’s Ethyol®, Amifostine for injection 500mg. This generic amifostine for injection is therapeutically equivalent to MedImmune’s Ethyol® Amifostine for injection 500mg. S-2-(3-Aminopropylamino) ethyl dihydrogen phosphorothioate (Amifostine) Ethyol® has annual sales of approximately USD 80 million in the US. Sun Pharma, being the first-to-file an ANDA for generic Ethyol® with a para IV certification, has a 180-day marketing exclusivity.Ethyol® is covered under 3 patents –
US5424471 (Expiry: July 31, 2012)-Covers crystalline Amifostine composition
US5591731 (Expiry: July 31, 2012)- Covers crystalline Amifostine composition with improved stability
US5994409 (Expiry: Dec 8, 2017)- Method of use
This ANDA was filed with para IV certification against all the patents. Medimmune filed a suit in the District Court of Maryland and the case is under litigation. Amifostine is used as an adjuvant in cancer treatment. Sun Pharma’s amifostine for injection will be indicated for the reduction of kidney damage in patients who have advanced ovarian cancer and are being given repeat doses of cisplatin.

web page statistics
Disclaimer: "IP Pharma Doc" blog is published for information purpose only. "IP Pharma Doc" blog contains no legal advice. I assume no legal responsibility for the views/information expressed here. “IP Pharma Doc” blog is my personal website and not edited by my employer, accordingly, no part of my blog should be attributed to my employer. All information on the present blog should be double checked for its accuracy and applicability. © Dr. Sarwal (2007)
 
eXTReMe Tracker